CLAIMS

Claim 1. Use of an anti-FcRn antibody or an antigen-binding fragment thereof in the manufacture of a medicament for treating or preventing Thyroid Eye Disease in a patient in need thereof, wherein the medicament is suitable for administration to the patient comprises (i) a therapeutically effective amount of the antibody or antigen-binding fragment; or (ii) a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody or antigen-binding fragment, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID No: 27 (HCDR1), an amino acid sequence of SEQ ID No: 28 (HCDR2), and an amino acid sequence of SEQ ID No: 29 (HCDR3); and a light chain variable region comprising an amino acid sequence of SEQ ID No: 30 (LCDR1), an amino acid sequence of SEQ ID No: 31 (LCDR2), and an amino acid sequence of SEQ ID No: 32 (LCDR3).

Claim 2. The use of claim 1, wherein the antibody or antigen-binding fragment comprises (i) a heavy chain variable region comprising an amino acid sequence of SEQ ID No: 6; and a light chain variable region comprising an amino acid sequence of SEQ ID No: 16 or (ii) a heavy chain variable region comprising an amino acid sequence that is at least 90% identical to SEQ ID No: 6; and a light chain variable region comprising an amino acid sequence that is at least 90% identical to SEQ ID No: 16.

Claim 3. The use of claim 1 or claim 2, wherein the antibody or antigen-binding fragment binds to FcRn with a KD (dissociation constant) of 0.01 to 2 nM at pH 6.0 or pH 7.4.

Claim 4. The use of any one of claims 1 to 3, wherein the antibody, antigen-binding fragment, or

pharmaceutical composition is to be administered subcutaneously.

Claim 5. The use of any one of claims 1 to 4, wherein the antibody, antigen-binding fragment, or pharmaceutical composition is to be administered as a fixed dose.

Claim 6. The use of any one of claims 1 to 5, wherein the antibody, antigen-binding fragment, or pharmaceutical composition is to be administered once weekly or once every 2 weeks (bi-weekly).

Claim 7. The use of any one of claims 1 to 6, wherein the therapeutically effective amount of the antibody or antigen-binding fragment is:

a. 200 to 300 mg, 300 to 400 mg, 400 to 500 mg, or 500 to 600 mg to be administered once weekly;

b. 340 mg to be administered once weekly;

c. 550 to 650 mg, 650 to 750 mg, or 750 to 850 mg to be administered once weekly; and/or

d. 680 mg to be administered once weekly.

Claim 8. The use of any one of claims 1 to 7, wherein the therapeutically effective amount of the antibody or antigen-binding fragment is at least one dose of about 680 mg, followed by at least one dose of about 340 mg.

Claim 9. The use of claim 8, wherein the at least one dose of about 680 mg is to be administered subcutaneously or intravenously and/or wherein the at least one dose of about 340 mg is to be administered subcutaneously.

Claim 10. The use of claim 8, wherein the at least one dose of about 680 mg is 3 doses and/or wherein the at least one dose of about 340 mg is 3 doses.

Claim 11. The use of any one of claims 1 to 10, wherein the antibody, antigen-binding fragment, or pharmaceutical composition is to be administered alone or in combination with at least one additional therapeutic agent.

Claim 12. The use of any one of claims 1 to 11, wherein treatment reduces the level of at least one IgG in a sample from the patient.

Claim 13. The use of claim 12, wherein the at least one IgG comprises anti-TSHR IgG and/or anti-IGF-1R IgG.

Claim 14. The use of claim 13, wherein treatment reduces the level of anti-TSHR IgG and/or anti-IGF-1R IgG in a sample from the patient by at least 30%, 40%, 50%, 60%, 70%, or 80%.

Claim 15. The use of any one of claims 1 to 14, wherein treatment reduces the level of total serum IgG in a sample from the patient.

Claim 16. The use of claim 15, wherein treatment reduces the level of total serum IgG in a sample from the patient by at least 40%, 50%, 60%, 70%, or 80%.